As part of a combination therapeutic strategy, targeting SHP2 via a selective inhibitor such as SHP099 [43] effectively inhibited the MAPK pathway and counteracted therapeutic resistance when combined with a MEK inhibitor in mutant KRAS-driven cancers [44,45,46,47]. The gene discussed is PTPN11; the disease is cancer.